European Journal of Medicinal Chemistry 2010-03-01

New 1,3-oxazolo[4,5-c]quinoline derivatives: synthesis and evaluation of antibacterial and antituberculosis properties.

Sumesh Eswaran, Airody Vasudeva Adhikari, R Ajay Kumar

Index: Eur. J. Med. Chem. 45 , 957-66, (2010)

Full Text: HTML

Abstract

A new class of fused oxazoloquinoline derivatives was synthesized starting from 2-bromo-1-phenylethanones 1a-b through multi-step reactions. The newly synthesized compounds were evaluated for their in vitro antibacterial against Escherichia coli (ATTC-25922), Staphylococcus aureus (ATTC-25923), Pseudomonas aeruginosa (ATCC-27853) and Klebsiella pneumoniae (recultured) and antituberculosis activity against Mycobacterium tuberculosis H37Rv (ATCC 27294). Preliminary results indicated that most of the compounds demonstrated very good antibacterial and antituberculosis activities which are comparable with the first line drugs. Compounds 6a, 6c, 6g, 6j, 6k and 6n emerged as the lead antitubercular agents with MIC, 1 microg/mL and 99% bacterial inhibition while eight compounds, viz., 5a, 15k, 6a, 6c, 6g, 6j, 6k and 6n were found to be more potent than INH (MIC: 1.5 microg/mL) with MIC 1 microg/mL.Copyright (c) 2009 Elsevier Masson SAS. All rights reserved.


Related Compounds

Related Articles:

Enhancement of in vitro activity of tuberculosis drugs by addition of thioridazine is not reflected by improved in vivo therapeutic efficacy.

2014-12-01

[Tuberculosis (Edinb.) 94(6) , 701-7, (2015)]

Disruption of an M. tuberculosis membrane protein causes a magnesium-dependent cell division defect and failure to persist in mice.

2015-02-01

[PLoS Pathog. 11(2) , e1004645, (2015)]

Kinetics of recA and recX induction in drug-susceptible and MDR clinical strains of Mycobacterium tuberculosis.

2014-12-01

[J. Antimicrob. Chemother. 69(12) , 3199-202, (2014)]

A trisubstituted benzimidazole cell division inhibitor with efficacy against Mycobacterium tuberculosis.

2014-01-01

[PLoS ONE 9(4) , e93953, (2014)]

Desmethyl bosentan displays a similar in vitro interaction profile as bosentan.

2015-02-01

[Pulm. Pharmacol. Ther. 30 , 80-6, (2015)]

More Articles...